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Blood vesselGalectins are carbohydrate binding proteins with versatile functions in tumor progression. Galectin-9, encoded
by LGALS9, has been associated with metastasis and immunosuppression. We previously reported on regulation
of LGALS9 expression during endothelial cell activation. Here, we show increased galectin-9 protein levels in the
endotheliumof different tumors, including carcinomas of the lung, liver, breast and kidney. Endothelial cellswere
found to expressﬁve LGALS9 splice variants, twoofwhichhave not been reported before. Splicingwas found to be
conﬁned to exons 5, 6 and 10. Transfection of humanmicrovascular endothelial cells (HMEC) with galectin-9Δ5,
a speciﬁc LGALS9 splice variant, induced a small but signiﬁcant increase of proliferation, while migration was not
affected by any LGALS9 splice variant. Application of recombinant galectin-9Δ5 protein dose-dependently re-
duced proliferation and migration of HMEC as well as human umbilical vein endothelial cells in vitro. Enhanced
sprouting andmigration of humanumbilical vein endothelial cell (HUVEC) towards a galectin-9Δ5 gradientwere
observed. Interestingly, galectin-9Δ5 was found to induce a small inhibitory effect on angiogenesis in vivo.
Collectively, these data show that endothelial cells regulate the expression and splicing of LGALS9 during angio-
genesis. The function of the dominant splice variant, i.e. galectin-9Δ5, in endothelial cell biology depends on the
concentration and environmental context in which it is presented to the cells.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Galectin-9 is a member of a family of glycan-binding proteins that
are characterized by the presence of one or two conserved carbohydrate
recognition domains (CRDs), i.e. galectins [1,2]. Galectin-9 belongs
to the subgroup of tandem-repeat galectins which have two CRDs
that are joined by a linker domain [2]. The protein of approximately
39.5 kD protein is encoded by LGALS9which consists of 11 exons [3]. Ex-
pression of galectin-9 is accompanied by extensive posttranscriptional
splicing which can regulate the length of the linker region between
both CRDs. Apart from the full length variant, which consists of
all exons (gal-9FL or gal-9L), two other LGALS9 splice variants are fre-
quently described in the literature, i.e. gal-9Δ5 (or gal-9M, lacking
exon 5) and gal-9Δ5/6 (or gal-9S, lacking exons 5 and 6) [3]. Splicing
of the linker encoding exons has been shown to inﬂuence galectin-9
valency and function [4,5].
Regarding its function in cancer, galectin-9 contributes to different
aspects of tumor growth and aggressiveness, including metastasis and
immunomodulation [3,6]. In fact, an inverse correlation betweenpartments of Medical Oncology
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ights reserved.LGALS9 expression and disease outcome has been reported in several
cancers, including breast, liver, skin, and cervix [7–10]. Moreover, it
has been suggested that galectin-9 might have clinical beneﬁt during
cancer treatment [3,11–14]. This requires a better understanding of
LGALS9 expression in different compartments of the tumor, including
the tumor vasculature. Previously, we reported on LGALS9 expression
in normal and tumor associated endothelial cells, i.e. the cells that
line the luminal side of all blood vessels [15]. Interestingly, altered endo-
thelial expression of LGALS1, LGALS3 and LGALS8 has been associated
with enhanced angiogenic activity in tumors [16–20]. Furthermore,
pro-angiogenic activity has been attributed to galectin-1 [21–24],
galectin-3 [19,25] and galectin-8 [17]. Here, we studied the expression
of LGALS9 as well as the function of galectin-9 in endothelial cell biology
and angiogenesis.
2. Materials and methods
2.1. Isolation of primary cells and cell culture
Primary human umbilical vein endothelial cells (HUVECs) were iso-
lated as described previously [15]. Quiescent HUVECs were directly
harvested from the umbilical cord without further culturing. Activation
of HUVEC was achieved by culturing the cells for at least three days in
culture medium supplemented with 20% human serum. This has al-
ready been shown to induce sufﬁcient EC activation causing alterations
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cular endothelial cell (HMEC-1) were cultured at 37 °C/5% CO2 in RPMI
(Gibco) containing 10% fetal calf serum (Invitrogen) and 10% human
serum supplemented with L-glutamine (Invitrogen) and penicillin/
streptomycin (Invitrogen).
Tumor endothelial cells were isolated from freshly resected kidney
tumor as described previously [26,27]. Cells were stored at −80 °C
until RNA isolation.
2.2. RNA isolation and cDNA synthesis
RNA was isolated using the RNeasy kit (QIAgen) according to the
supplier's protocol. Isolations were subjected to on-column DNaseI di-
gestion (QIAgen). The purity and concentration of the RNA samples
were determined by spectrophotometry (ND-1000, Nanodrop Technol-
ogies). cDNA synthesis was performed on 500 ng total RNA using the
iScript cDNA synthesis kit (BioRad) according to the supplier's protocol.
2.3. Real-time PCR
Real time PCR was performed on the CFX96 real time PCR detection
system (BioRad). In short, 1.5 μL of cDNA was used in a total reaction
volume of 25 μL containing 1× SensiMix (Quantace) and 400 nmol/L
of LGALS9 splice variant speciﬁc primers (Supplementary Table 1). A
standard 2-step ampliﬁcation protocol was used with Tm = 61 °C
followed by a melting curve analysis. Measurements were performed
on at least 3 different HUVEC isolations or in triplicate for cell lines. To
compare expression levels between different conditions, the ΔΔCt
method was used as described previously [15].
2.4. Cloning of galectin-9 splice variants
Endothelial LGALS9 splice variants were cloned from HUVEC cDNA
into the pCR2.1 TOPO vector using the TOPO TA cloning kit (Invitrogen).
LGALS9ﬂanking primerswere used for the cloning PCR (forward primer:
5′-ATGGCCTTCAGCGGTTCC; reverse primer 5′-CTATGTCTGCACATGGGT
CAG). Ligation products were transformed into OneShot TOP10
Escherichia coli (Invitrogen) and grown overnight on LB plates con-
taining ampicillin. Positive clones were selected by insert PCR with
M13 primers. Midipreps were performed with the QiaPrep Spin
Midiprep kit (Qiagen), according to the supplier's protocol. To obtain
eukaryotic expression, all LGALS9 splice variants were directionally
cloned into pcDNA3.1 using HindIII/XhoI digestion and subsequent li-
gation with T4 DNA Ligase (New England Biolabs). Successful cloning
was conﬁrmed by restriction enzyme digestion and sequence analysis
which was performed by BaseClear (Leiden, the Netherlands).
2.5. Transfection
For gain of function experiments, HMEC were seeded in 96-well
plates coated with 0.2% gelatin/PBS at a density of 1.5 × 104 cells/well.
The next day, the subconﬂuent cellswere transfectedwith the appropri-
ate constructs using lipofectamine LTX and PLUS reagent (Invitrogen)
according to the supplier's protocol. 72 h following transfection,
functional assays, i.e. migration and proliferation, were performed. In
addition, expression of galectin-9 variants was conﬁrmed by Western
blot as described below.
2.6. In vitro proliferation and migration assays
To assess the effect of endogenous galectin-9 expression on endo-
thelial cell proliferation and migration, HMEC were transfected with
LGALS9 splice variants and used in functional assays 72 h post transfec-
tion. To assess the effect of exogenous galectin-9 variants, HUVECs
or HMEC were incubated with a concentration range of exogenous re-
combinant galectin-9D5 (R&D systems) or only the N-terminal CRD ofgalectin-9 (gal-9N; kind gift from Dr. H. Lefﬂer) for 48 h (proliferation)
or during the scratch assay (migration). The CellTiter-Glo assay
(Promega) was used to assess the proliferation rate of endothelial
cells. In short, cells in a 96 well plate were washed and incubated with
100 mL CellTiter-Glo reagent for 10 min on a shaker. Next, lumines-
cence levels were determined on amicroplate reader (Tecan). Endothe-
lial cell migrationwas assessed by creating a scratch in a conﬂuent layer
of endothelial cells, followed bymonitoring of its closure. Images of each
scratchwere automatically acquired at t = 0 and t = 8 hwith a 1.4 Mb
GiGE color camera (Hitachi) on a DMI3000B microscope equipped with
an automated xyz-stage (Leica) using Universal Grab software (version
6.3, DCILabs). Scratch area was determined using Scratch Assay
software (version 6.2, DCILabs). Proliferation experiments following
HMEC transfection were performed in quadruplicate with four repli-
cates of treatment conditionswithin each experiment. Migration exper-
iments following HMEC transfection were performed in quintuplicate
and within each experiment there were at least three replicates of all
treatment conditions. Proliferation and migration with recombinant
galectin-9 on HMEC and HUVEC were performed in triplicate with
three replicates per treatment condition within each experiment.
2.7. Sprouting
For sprouting, HUVECs were resuspended to a ﬁnal concentration of
40,000 cells/mL in methocel medium (RPMI with 20% methocel and
10% heat-inactivated human serum). Next, 25 μL drops were pipetted
onto the lid of a non-adhesive square petri dish which was then
inverted and incubated overnight in a humidiﬁed incubator at 37 °C,
5% CO2. The next day, the spheroids were harvested in PBS. For each
experimental condition approximately 40 spheroids were resuspended
in 200 μL matrigel and transferred to a 24-well plate. Following solidiﬁ-
cation of the matrigel 500 μL medium was applied and spheroids were
allowed to sprout in a humidiﬁed incubator at 37 °C, 5% CO2 for
16–24 h. Finally, pictures of the spheroidswere taken and sprout length
and sprout number per spheroidwere analyzed using ImageJ. All exper-
iments were performed in triplicate and per experiment at least 20
spheroids per condition were analyzed.
2.8. Transwell migration
For transwell migration, 7500 HUVECs were seeded in HTS
FluoroBlok inserts (8 micrometer pore size, Falcon). Inserts were placed
in 24-well plates containing culture medium supplemented with the
appropriate compounds. Cells were allowed to migrate overnight.
Next, cells were ﬁxed with 1% paraformaldehyde in 0.1% BSA/PBS.
Following three wash stepswith PBS, cells were stained with phalloidin
red in 0.1% Triton/PBS overnight at 4 °C. Images were acquiredwith LAS
v3.7 software (Leica) using an inverted ﬂuorescent microscope (DM-IL
Leica) equipped with a DFC345 FX camera (Leica). The number of cells
was scored in 5 random selected areas by two independent observers.
Experiments were performed in triplicate.
2.9. Galectin-9 secretion
To assess the secretion of galectin-9 by endothelial cells, transfected
HMEC were grown for 48 h in culture medium after which the cells
were washed with PBS and continued to grow in serum-free medium.
After 24 h, the serum-free medium was collected for Western blot
analysis.
2.10. Western blotting
ForWestern blot analysis, cells were lysed in the culture plates using
cell lysis buffer (Cell Signaling) supplemented with protease inhibitors
according to the supplier's protocol. Protein concentrations were deter-
mined using the BCA protein assay (Pierce). Subsequently, 30 μg of
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with 1:20 β-mercapto-ethanol. Samples were boiled for 5 min and
immediately separated by gel electrophoresis on a 15% polyacrylamide
gel and transferred onto PVDF membranes (Millipore) following stan-
dard protocols. Membranes were blocked with Odyssey blocking buffer
(LI-COR Biosciences) for 1 h and incubated overnight at 4 °C with goat
anti-galectin-9 antibody (1:500, R&D systems), which recognizes
the N-terminal part of galectin-9. Equal loading of the gels was con-
ﬁrmed by α-actin detection using mouse anti-α-actin (1:10,000,
MP Biomedicals). The membranes were washed three times with
PBS/0.1% Tween and subsequently incubated with the appropriate
secondary IRDye antibodies (IRDye 800 anti-goat and IRDye 800
anti-mouse, LI-COR Biosciences) for 1 h at room temperature. Finally,
membranes were washed two times with PBS/0.1% Tween and rinsed
with PBS. Images were obtained by scanning the membranes with the
Odyssey infrared imaging system (LI-COR Biosciences).
2.11. Immunohistochemistry
Galectin-9 immunohistochemistry was performed on tissue-
microarrays of 4 different cancer types (Super Bio Chips); kidney (CL),
liver (CSA), lung (CCA) and breast (CBA) according to the supplier's
protocol. Each array contains 50 tumor sections and 9 matched control
sections, i.e. sections made from adjacent non-malignant tissue. As
a primary antibody, we used a polyclonal goat anti-human galectin-9
antibody (1:500, R&D systems). Galectin-9 was visualized by DABFig. 1. Galectin-9 protein expression on the tumor endothelium. a) Representative images of im
tissue (lower panels) from lung, liver, breast and kidney. Insets show endothelial cell staining. b
and tumor (avg T) tissues. * p b 0.05. c) Diagrams showing average galectin-9 staining score instaining of a polyclonal HRP-conjugated rabbit-anti-goat secondary an-
tibody (DAKO 1:500). Blind scoringwas performed by two independent
observers who ﬁrst assessed the overall staining intensity on a single
array. Next, we used a 3-step scoring scale to score individual sections:
0 for absent or very low staining, 1 for moderate staining and 2 for
strong staining. Scoring was performed for both tumor cells (their
non-malignant counterparts) and endothelial cells.
2.12. Chick chorioallantoic membrane assay
Fertilized chicken eggs (Het Anker, the Netherlands) were incubated
and rotated at a relative air humidity of 65% and a temperature of 37.6 °C
in a hatching incubator with an automatic rotator for 3 days. On embry-
onic day 3 (EDD3), a small opening of approximately 3 mm in diameter
wasmade in the eggshell at the top of the egg and sealed with tape. The
eggs were then incubated for 3 days with the opening facing upwards.
On EDD6, the eggs were opened further to allow easier access to the
chorioallantoic membrane. For the topical application of recombinant
galectins, polyethylene rings were deposited on the CAM. From embry-
onic EDD6 to EDD9, recombinant galectins were applied daily within
the polyethylene rings. Finally, on EDD10, pictures of the chorioallantoic
membrane were taken using an Optech LFZ stereomicroscope (Optech)
after injection of approximately 1 mL contrast agent (zinc oxide in pure
vegetable oil) under the chorioallantoicmembrane and the ring. Quanti-
ﬁcation of different vascular parameters was obtained using HetCAM
software (Peira, Belgium). At least 8 eggs per condition were used.munohistochemical staining of galectin-9 in normal tissue (upper panels) and cancerous
) Diagrams showing average galectin-9 staining score in endothelial cells of normal (avg N)
epithelial cells of normal (avg N) and tumor (avg T) tissues. * p b 0.05.
287R. Heusschen et al. / Biochimica et Biophysica Acta 1842 (2014) 284–2922.13. Statistical analyses
All data are presented asmean ± semunless indicated otherwise. For
testing, the Mann–Whitney rank sum test was used. p-values b 0.05
were considered statistically signiﬁcant and all statistical analyses were
performed using SPSS (SPSS Inc., Gorinchem, the Netherlands).
3. Results
3.1. Galectin-9 protein levels are increased on the tumor endothelium of
solid tumors
Wehave previously reported on galectin-9 expression in normal and
tumor endothelium [15]. To get more insight in endothelial galectin-9
expression, we performed immunohistochemical staining on tissue
sections from 4 types of solid tumors and their normal counterparts,
i.e. lung, liver, breast, and kidney. Interestingly, all four tumor types
displayed increased galectin-9 protein levels in the tumor endothelial
cells as compared to the normal endothelium (Fig. 1a). Subsequent
scoring indicated that endothelial galectin-9 staining in most tumors
was signiﬁcantly increased compared to normal endothelium (Fig. 1b).
Tumor cell expression did not change as compared to normal epithe-
lium, except for kidney (Fig. 1c). Thus, endothelial cells show elevated
galectin-9 protein levels in a tumor micro-environment pointing to-
wards a role for galectin-9 in tumor angiogenesis.
3.2. Endothelial cells express ﬁve LGALS9 splice variants
To get more insight in the function of galectin-9 in endothelial
biology we ﬁrst determined LGALS9 expression in endothelial cells.
Since LGALS9 transcripts are subject to extensive splicing we set out to
identify and characterize all LGALS9 splice variants in endothelial cells.Fig. 2. LGALS9 expression in endothelial cells. a) Schematic representation of endothelial LGALS9
exons coding for the linker region are shown as dotted lines. Gal-9FL, gal-9Δ5 and gal-9Δ5/6 var
truncated C-terminal CRD. b) LGALS9 splice variant expression levels in quiescent HUVEC asse
expression upon HUVEC activation relative to expression in quiescent cells (n = 3). Total LGA
expression was used as a positive control.To that end, a PCR was performed on HUVEC cDNA with primers
ﬂanking the open reading frame of the full length LGALS9 transcript,
i.e. the transcript containing all 11 exons (Gal-9FL). The PCR products
were cloned into the pCR2.1 T/A cloning vector and clones were
screened for different insert lengths by insert PCR and restriction
enzyme digestion (Supplementary Fig. 1). This approach identiﬁed 5
different LGALS9 splice variants which were further characterized by
sequence analysis. This identiﬁed three transcripts that have already
been described, i.e. gal-9FL (Full length, containing all 11 exons), gal-
9Δ5 (lacking exon 5) and gal-9Δ5/6 (lacking exons 5 and 6). In the
two additional splice variants the splicing of exon 5 or exons 5/6was ac-
companied by splicing of exon 10 resulting in gal-9Δ5/10 and gal-9Δ5/
6/10, respectively. Exclusion of exon 10 from the mature transcript
caused a frame-shift, resulting in a premature stop codon in exon 11
and a truncated C-terminal CRD (Fig. 2a and Supplementary Fig. 1).
To conﬁrm that the cloned variants indeed compromise the en-
tire endothelial repertoire of LGALS9 splice variants, real-time PCR
was performed on HUVEC cDNA with splice-variant speciﬁc primers
(Supplementary Table 1). All primer combinations were analyzed for
speciﬁcity and sensitivity (Supplementary Fig. 2). In accordance with
the cloning data, the real-time PCR analysis indicated that LGALS9 ex-
pression in endothelial cells is restricted to 5 transcripts, i.e. gal-9FL,
gal-9Δ5, gal-9Δ5/6, gal-9Δ5/10, and gal-9Δ5/6/10 (Fig. 2b). Real-time
PCR also indicated that gal-9Δ5 is themost abundantly expressed splice
variant in quiescent endothelial cells. Gal-9Δ5/6/10 expression was the
lowest while the remaining three splice variants were expressed at
comparable levels. None of the other potential splice variants varying
in exons 5, 6 and 10 were expressed at detectable levels. The latter
was also observed when LGALS9 splice variant expression was assessed
in endothelial cells that were derived from freshly resected tumors as
described previously [27] (Supplementary Fig. 3). To evaluate splicing
of other exons we also performed an in silico analysis to search forsplice variants and protein isoforms. CRDs and their coding exons are shown in black, the
y in their linker length. Gal-9Δ5/10 andGal-9Δ5/6/10 vary in their linker length and have a
ssed by qPCR (n = 3 independent HUVEC isolations). c) Change in LGALS9 splice variant
LS9 indicates detection of all galectin-9 splice variants concomitantly. LGALS1 (galectin-1)
Table 1
LGALS9 expression in human cell lines of different origin.
Source Cell line FL D5 D5/6 D5/10 D5/6/10
Endothelium HUVEC + ++ + + +
EC-RF24 − ++ + + +
HMEC − ++ − + +
Colon HCT116 − − − − −
HT29 ++ + + + +
Colo205 ++ + + + +
Colo320 ++ + − − +
LS174T ++ − − − −
Caco2 − − − − −
Blood Jurkat ++ + − + +
Liver HepG2 − − − − −
Breast MCF7 − − − − −
MD231 − ++ − − −
Skin MUM2B − − − − −
MUM2C − − − − −
C8161 − − − − −
C81-61 − ++ − + +
Kidney HEK293T − − − − −
Miscellaneous Fibroblasts − ++ − − +
HeLa + + ++ − +
EW7 − − − − −
A2780 − − − − −
+ = splice variant detected,− = splice variant not detected, ++ = dominant splice
variant.
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consensus splicing sites were only found for all known exons (Supple-
mentary Table 2). In addition, both the ASPic and SpliceNest databases
[28,29] predicted alternative splicing of only exons 5, 6 and 10 in sufﬁ-
ciently long protein-coding transcripts of LGALS9. Altogether, these data
suggest that alternative splicing of LGALS9 transcripts is restricted to
exons 5, 6 and 10.
Since most of the studies that reported on LGALS9 expression in cells
and tissues of different origin did either not discriminate between
different splice variants or determined the expression of only a few
variants we determined the complete LGALS9 splice variant expressionFig. 3. Effects of galectin-9 splice variant expression on HMEC proliferation and migration. a) S
bered white boxes. White arrows indicate start codons, black arrows indicate stop codons. b)W
splice variant expression vectors 72 h following transfection. Equal protein loading was conﬁ
galectin-9 splice variants (n = 4). * p b 0.05. d) Relative inhibition of HMEC migration followiproﬁle in a panel of human cell lines of different origin. These data
show that the expression and relative abundance of LGALS9 splice
variants vary between these cell lines, suggesting diverging activities
in cell biology (Table 1).
3.3. LGALS9 splice variant expression is altered following endothelial cell
activation
To determine whether the expression of individual splice variants
was differentially affected by endothelial cell activation, we assessed
the expression in quiescent and activated HUVEC by real-time PCR. In
line with previous ﬁndings we observed that endothelial cell activation
in vitro results in a signiﬁcant decrease of overall LGALS9mRNA expres-
sion levels (Fig. 2c). This was predominantly caused by a decrease in
gal-9Δ5 levels, themost abundantly expressed splice variant. Compared
to the overall LGALS9 expression, the relative mRNA expression levels
of the splice variants lacking exon 6, i.e. gal-9Δ5/6 and gal-9Δ5/6/10,
increased upon endothelial cell activation (Fig. 2c).
3.4. Galectin-9 modulates endothelial cell function
The observation that tumor endothelial cells in vivo have elevated
galectin-9 levels while endothelial cell activation in vitro is accompa-
nied by a decreased expression urged us to investigate the role of
galectin-9 in angiogenesis. To that end, we cloned and expressed the
speciﬁc LGALS9 splice variants in human microvascular endothelial
cells (HMEC), which have low levels of endogenous galectin-9 mRNA
(Fig. 3a+b). Subsequent functional analyses revealed amodest increase
in endothelial cell proliferation which reached statistical signiﬁcance
for gal-9Δ5 while here was no effect on migration (Fig. 3c+d). Next,
we determined whether exogenous application of galectin-9 could
modulate endothelial cell function, similar to that described for other
galectins [17,19,23]. First, we established whether endothelial cells
can secrete galectin-9 in the supernatant. Western blot analysis of
supernatants collected from HMEC transfected with different LGALS9
splice variants suggested that secretion of detectable protein levels ischematic representation of galectin-9 expression constructs. Exons are indicated by num-
estern blot of galectin-9 protein expression in HMEC transfected with different galectin-9
rmed by actin (Act) staining. c) Relative HMEC proliferation following overexpression of
ng overexpression of galectin-9 splice variants (n = 5).
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dominant endothelial splice variant which is also available as a recom-
binant protein, we further focused on the effects of this variant. First,
we performed a proliferation assay using different galectin-9Δ5 concen-
trations. In contrast to the experiments with increased endogenous
expression we observed that exposure of HMEC to galectin-9Δ5 did
not affect proliferation, except for a high concentration of 500 nM
(Fig. 4b). The same was observed for HMEC migration in the presence
of galectin-9Δ5 (Fig. 4c). On the other hand, in primary isolated
human umbilical vein endothelial cells, we did observe effects on cell
proliferation and migration at lower galectin-9Δ5 concentrations
(Fig. 4d+e). Interestingly, when sprouting in a 3D environment was
analyzed we observed that adding galectin-9Δ5 directly to matrigel
did not affect sprout formation while applying the protein topically in
the medium resulted in increased sprout formation (Fig. 5a). This sug-
gests that galectin-9Δ5 might serve as a chemoattractant for HUVEC.
Indeed, in a transwell migration assay more cells migrated towards
the galectin-9Δ5 containing medium as compared to the medium
without galectin-9Δ5 (Fig. 5b). All these in vitro data suggest that the
contribution of galectin-9Δ5 to endothelial cell function depends on
the concentration and context in which the protein is presented to the
cell. To get a better insight in the overall role in angiogenesis in vivo,
we ﬁnally determined the effects of exogenous galectin-9Δ5 using the
chick chorioallantoic membrane (CAM) assay. Here, application ofFig. 4. Effect of exogenous galectin-9Δ5 on endothelial cell proliferation andmigration. a)Weste
galectin-9Δ5 and galectin-9Δ5/6. Blank represents cells treated with transfection reagent only
of HMEC (b) and HUVEC (d) following treatment with recombinant gal-9Δ5 for three days (n
treatment with recombinant gal-9Δ5 (n = 3). * p b 0.05.recombinant galectin-9Δ5 induced a signiﬁcant reduction in the num-
ber of vessel endpoints at 100 and 500 nM concentrations (Fig. 5c).
4. Discussion
We have previously shown that endothelial cells predominantly ex-
press galectin-1, -3, -8 and -9 [15].While galetin-1, -3, and -8 have been
linked to endothelial cell biology [17,19,22,23,30], little is known re-
garding the function of galectin-9 in endothelial cells. Here, we report
on the expression and function of LGALS9 splice variants in endothelial
biology. To our knowledge, this is theﬁrst study inwhich the expression
of all splice variants of LGALS9 is assessed in endothelial cells. Alterna-
tive splicing of LGALS9 has been reported in cells and tissues of different
origin. Three main variants have been described in which splicing
appears to be conﬁned to the exons encoding the linker between the
two CRDs, i.e. exons 5 and 6 [31–33]. Endothelial expression of these
3 LGALS9 splice variants was ﬁrst reported by Spitzenberger et al.
[32] and later conﬁrmed by others [15,34]. Here, we described two
additional splice variants which lack exon 10 next to exon 5 or exons
5/6. Thus far, expression of gal-9Δ5/10 has only been reported by
Lipkowitz in cells of non-endothelial origin, i.e. colon epithelial cells
and peripheral blood lymphocytes [35]. The variant lacking all three
exons, i.e. gal-9Δ5/6/10, has not been described before to our knowl-
edge. Further expression proﬁling of the LGALS9 splice variants in arn blot showing detectable galectin-9 protein in the supernatant of HMEC transfectedwith
. Mock represents cells transfected with empty vector. b + d) Relative proliferation rate
= 3). * p b 0.05. c + e) Relative inhibition of HMEC (c) and HUVEC (e) migration upon
Fig. 5. Galectin-9Δ5 acts as chemoattractant and inhibits in vivo angiogenesis. a) Analysis of endothelial cell sprouting in the presence and absence of Galectin-9Δ5 (100 nM). Left panels
show representative spheroids incubated for 24 h in matrigel with no galectin-9Δ5 (top), galectin-9Δ5 in matrigel (middle) or galectin-9Δ5 in medium topically applied (bottom). The
panel shows the relative change in sprout number and sprout length as scored in 20 spheroids per condition in three independent experiments. * p b 0.05. b) Transwell migration of
HUVEC towards galectin-9Δ5 (100 nM). The images show phalloidin red/DAPI staining of cells that migrated over a membrane with 0.8 micrometer pores (black dots). Diagram
shows the relative change in number of cells that migrated over the membrane towards medium with or without galectin-9Δ5. Five microscopic ﬁelds were scored per condition in
three independent experiments. * p b 0.05. c) In vivo analysis of galectin-9Δ5 activity on angiogenesis using the chicken chorioallantoic membrane assay. Bottom panels show represen-
tative images of CAMs after treatment with different gal-9Δ5 concentrations (n = 9 eggs/condition). Diagrams show the quantiﬁcation of vessel length, branch points and end points as
determined with the HetCAM software. * p b 0.05.
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in agreement with a previous study [36]. In addition, our current data,
together with the in silico data provided by splicing prediction algo-
rithms, suggest that the splicing of LGALS9 is conﬁned to exons 5, 6,
and 10. The regulatory mechanisms underlying this extensive splicing
still need to be resolved. In addition, the functional consequence of
splicing is still poorly understood. Exclusion of exons 5 and 6 affects
the length and rotational freedom of the linker domain between
the two CRDs which inﬂuences higher-order multimer formation and
gal-9 valency [4,5]. Thus,while both theN- and C-terminal CRDs already
vary in the glycoconjugate speciﬁcity and afﬁnity [37,38], the carbohy-
drate binding might be further regulated by splicing. In addition, exon
6 appears to contain a myristoylation site which potentially confers
a co-translational modiﬁcation that has been associated with signal
transduction and membrane targeting [39]. Whether exon 6 lacking
variants indeed have a different cellular distribution compared to
the other splice variants remains to be determined. Finally, the linker
contains protease sensitive sites allowing cleavage of the protein into
two single CRDs [40,41] while exclusion of exon 10 gives rise to a trun-
cated C-terminal CRD. Although the latter has been observed for gal-8,another tandem-repeat galectin [42] it is still unknown what the func-
tional consequence of this truncation is. Given the functional impor-
tance of bivalent carbohydrate binding by galectins, the loss of the
second CRD, either by proteolytic cleavage or by splicing of exon 10
might generate a dominant negative protein. In support of this it has
been shown that eosinophil chemoattractant activity differs among
the LGALS9 splice variants [43] and that it relies on the bivalent activity
of galectin-9 as the complete protein is more active compared to the
separate CRDs [44]. Different splice variants have also been shown to
differentially affect E-selectin expression in colon carcinoma cells there-
by modulating the adhesion of the cells to endothelial cells [9]. While
we did not assess adhesion, we did observe that galectin-9Δ5 can act
as chemoattracting agent for endothelial cell. This effect, as well as the
modulation of proliferation and migration by galectin-9Δ5, appears
to depend on the cellular context since application of exogenous
galectin-9Δ5 hampered cell proliferation while endogenous overex-
pression induced proliferation. In addition, we observed a biphasic
effect of exogenous galectin-9Δ5 endothelial cell migration which
was also described for galectin-1 [23]. Thus, regulation of cellular func-
tions by galectin-9Δ5, and most likely also by other galectin-9 variant
291R. Heusschen et al. / Biochimica et Biophysica Acta 1842 (2014) 284–292depends on local concentration and localization. Nevertheless, the
effects of galectin-9Δ5 on angiogenesis in vivo appear to be less as
compared to other endothelial galectins like galectin-1 [18], galectin-3
[19] and galectin-8 [17]. Whether this is also true for other galectin-9
variants, this still needs to be investigated.
Despite the lack of strong angiogenic activity we did observe that
endothelial galectin-9 protein levels signiﬁcantly increase in 4 types of
solid tumors, i.e. kidney, liver, lung and breast tumors. This appears to
contradict with ﬁndings in vitro where galectin-9 protein levels de-
creased upon endothelial cell activation [15]. Most likely this is due to
thepresence of a complex tumormicroenvironment in tumorswith spe-
ciﬁc growth factors, cytokines and other environmental queues that are
not present in the in vitro setting. For example, IFN-γ has been shown to
induce galectin-9 expression in endothelial cells [34,45] and is now also
implicated as a tumorigenic factor [46]. Alternatively, the endothelial
galectin-9 might have been secreted by other (tumor) cells and conse-
quently taken up by endothelial cells, as shown for galectin-1 [23].
The increased expression of endothelial galectin-9 might be in-
volved in tumor immune escape. Galectin-9 has a well-documented
role in the modulation of the activity and the survival of immune cells
[47]. While initially discovered as an eosinophil chemoattractant [48],
subsequent studies demonstrated that the protein induces apoptosis
potently in Th1 cells [49] and in cytotoxic T cells via its receptor Tim-3
[50] although Tim-3 independent signaling of galectin-9 has also been
reported [51]. Possibly, increased endothelial galectin-9 expression in
the tumor vasculature could contribute to tumor immune escape by
providing an immunosuppressive environment. Furthermore, it might
be that endothelial galectin-9 inhibits transendothelial migration of
leukocytes independent of its apoptotic activity, similar to that de-
scribed for galectin-1 [52]. Whether and how these and other immuno-
modulatory activities are induced by the different endothelial galectin-9
splice variants remains to be established.
Taken together, our data show that galectin-9 protein levels are
increased in the tumor endothelium. Furthermore, endothelial cells
express ﬁve different galectin-9 splice variants which are differentially
regulated during endothelial cell activation. The function of galectin-9
in endothelial cell biology and angiogenesis depends on cellular locali-
zation, local concentration and the context in which the protein is pre-
sented to the cells.
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